These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 25930118)

  • 1. Fabrication of cell culture-derived influenza vaccine dissolvable microstructures and evaluation of immunogenicity in guinea pigs.
    Bonificio A; Ghartey-Tagoe E; Gallorini S; Baudner B; Chen G; Singh P; O'Hagan DT; Kommareddy S
    Vaccine; 2015 Jun; 33(25):2930-8. PubMed ID: 25930118
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influenza subunit vaccine coated microneedle patches elicit comparable immune responses to intramuscular injection in guinea pigs.
    Kommareddy S; Baudner BC; Bonificio A; Gallorini S; Palladino G; Determan AS; Dohmeier DM; Kroells KD; Sternjohn JR; Singh M; Dormitzer PR; Hansen KJ; O'Hagan DT
    Vaccine; 2013 Jul; 31(34):3435-41. PubMed ID: 23398932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved immunogenicity of individual influenza vaccine components delivered with a novel dissolving microneedle patch stable at room temperature.
    Vassilieva EV; Kalluri H; McAllister D; Taherbhai MT; Esser ES; Pewin WP; Pulit-Penaloza JA; Prausnitz MR; Compans RW; Skountzou I
    Drug Deliv Transl Res; 2015 Aug; 5(4):360-71. PubMed ID: 25895053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dissolvable microneedle patches for the delivery of cell-culture-derived influenza vaccine antigens.
    Kommareddy S; Baudner BC; Oh S; Kwon SY; Singh M; O'Hagan DT
    J Pharm Sci; 2012 Mar; 101(3):1021-7. PubMed ID: 22190403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB; Neuzil KM; Zhu Y; Fairchok MP; Gagliano ME; Monto AS; Englund JA
    Pediatrics; 2006 Sep; 118(3):e570-8. PubMed ID: 16950948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
    Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
    Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation of highly concentrated influenza vaccine for use in novel delivery approaches.
    Kommareddy S; Bonificio A; Gallorini S; Baudner B; Singh M; O'Hagan D
    J Pharm Sci; 2013 Mar; 102(3):866-75. PubMed ID: 23303584
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of broad immunity by thermostabilised vaccines incorporated in dissolvable microneedles using novel fabrication methods.
    Vrdoljak A; Allen EA; Ferrara F; Temperton NJ; Crean AM; Moore AC
    J Control Release; 2016 Mar; 225():192-204. PubMed ID: 26774221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection of guinea pigs by vaccination with a recombinant swinepox virus co-expressing HA1 genes of swine H1N1 and H3N2 influenza viruses.
    Xu J; Yang D; Huang D; Xu J; Liu S; Lin H; Zhu H; Liu B; Lu C
    Arch Virol; 2013 Mar; 158(3):629-37. PubMed ID: 23135159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An H1-H3 chimeric influenza virosome confers complete protection against lethal challenge with PR8 (H1N1) and X47 (H3N2) viruses in mice.
    Abdoli A; Soleimanjahi H; Tavassoti Kheiri M; Jamali A; Mazaheri V; Abdollahpour Alitappeh M
    Pathog Dis; 2014 Dec; 72(3):197-207. PubMed ID: 25066138
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T; Block SL; Guerra F; Lattanzi M; Holmes S; Izu A; Gaitatzis N; Hilbert AK; Groth N
    Pediatr Infect Dis J; 2012 May; 31(5):494-500. PubMed ID: 22301476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin.
    Bright RA; Carter DM; Daniluk S; Toapanta FR; Ahmad A; Gavrilov V; Massare M; Pushko P; Mytle N; Rowe T; Smith G; Ross TM
    Vaccine; 2007 May; 25(19):3871-8. PubMed ID: 17337102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemagglutinin stem reactive antibody response in individuals immunized with a seasonal influenza trivalent vaccine.
    Zhao X; Qin K; Guo J; Wang D; Li Z; Zhu W; Liu L; Wang D; Shu Y; Zhou J
    Protein Cell; 2015 Jun; 6(6):453-457. PubMed ID: 25940943
    [No Abstract]   [Full Text] [Related]  

  • 15. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
    Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
    Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insertion-responsive microneedles for rapid intradermal delivery of canine influenza vaccine.
    Choi IJ; Kang A; Ahn MH; Jun H; Baek SK; Park JH; Na W; Choi SO
    J Control Release; 2018 Sep; 286():460-466. PubMed ID: 30102940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-protection against homologous drift variants of influenza A and B after vaccination with split vaccine.
    Heckler R; Baillot A; Engelmann H; Neumeier E; Windorfer A
    Intervirology; 2007; 50(1):58-62. PubMed ID: 17164559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
    Jo YM; Song JY; Hwang IS; Lee J; Oh SC; Kim JS; Kim SR; Kim WJ; Cheong HJ
    J Med Virol; 2009 Apr; 81(4):722-7. PubMed ID: 19235853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influenza antigen-sparing by immune stimulation with Gram-positive enhancer matrix (GEM) particles.
    Saluja V; Visser MR; Ter Veer W; van Roosmalen ML; Leenhouts K; Hinrichs WL; Huckriede A; Frijlink HW
    Vaccine; 2010 Nov; 28(50):7963-9. PubMed ID: 20946860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity of a 2009 pandemic influenza virus A H1N1 vaccine, administered simultaneously with the seasonal influenza vaccine, in children receiving chemotherapy.
    Ottóffy G; Horváth P; Muth L; Sólyom A; Garami M; Kovács G; Nyári T; Molnár D; Pauler G; Jankovics I
    Pediatr Blood Cancer; 2014 Jun; 61(6):1013-6. PubMed ID: 24395342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.